Kohl's Posts Smaller Q1 Loss, Sticks to Full-Year Forecast

Published 1 days agoKSS

Kohl's Posts Smaller Q1 Loss, Sticks to Full-Year Forecast

Kohl's Corporation surpassed analyst expectations with its first-quarter 2025 earnings report, announcing a smaller than anticipated loss. The company reported a loss of $0.13 per share, improving over its earlier estimate of a $0.20 to $0.24 loss and beating analysts' forecast of a $0.26 loss, Reuters reported.

Even though comparable sales declined by 3.9%, this was slightly less severe than the predicted 4% to 4.3% drop. Kohl's is also maintaining its full-year sales outlook with projections of a 5% to 7% decline and anticipates annual earnings per share to range between $0.10 and $0.60. In response to the latest earnings news, Kohl's shares rose by 6% in premarket trading.

Kohl's is committed to strategic changes, focusing on closing underperforming locations and bolstering its collaboration with Sephora. The retailer plans to expand its Sephora presence to over 1,100 mini-stores within Kohl's by the end of the year. These steps demonstrate the retailer's ongoing efforts to adapt and strengthen its market position.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Costco's Q3 Earnings: Strong EPS and Market Response

Costco's Q3 Earnings: Strong EPS and Market Response

6 minutes agoCOST

Costco Wholesale Corporation recently announced its fiscal third-quarter earnings, showcasing strong earnings per share (EPS) while facing some sales challenges. The company reported an EPS of $4.28, which slightly surpassed analysts' projections of $4.24. Total revenue reached $61.96 billion, reflecting an 8% year-over-year increase, though it fell short of the forecasted $63.19 billion, according to Reuters. Same-store sales were a highlight, as they increased by 8% compared to projections of 6.96%, excluding gas sales. Despite outperforming on EPS and same-store sales, Costco's stock remained steady in after-hours trading, preserving a 10% rise year-to-date. To adapt to economic shifts, particularly U.S. tariffs on Chinese goods, Costco has rerouted shipments and shifted highly taxed products to markets outside the U.S. The retailer maintains a commitment to cost control, indicating that raising prices would be a last resort. Costco's strategy of offering private label products and bulk quantities continues to draw in value-conscious consumers, bolstering its sales performance.

Gap's Shares Plunge 15% Due to Tariff Impact Announcement

Gap's Shares Plunge 15% Due to Tariff Impact Announcement

21 minutes agoGPS

Gap Inc. faced a significant stock decline, with shares dropping about 15% following its announcement about the financial impact of U.S. tariffs. The company revealed that the tariffs imposed during President Trump's administration could affect its annual operating income by around $250 million to $300 million. As Reuters reported, this stark revelation caused concern among investors, leading to the sharp fall in share prices. To mitigate the impact, Gap has devised a plan to offset more than half of these costs, although it has not included the impact of these tariffs in their fiscal forecasts. The company’s decision to exclude the tariff impact from its forecasts was a significant factor contributing to investor anxiety. Despite these concerns, Gap still projects a promising future, maintaining its 2025 outlook which anticipates 1% to 2% sales growth and an 8% to 10% increase in operating income. In response to the tariffs, CEO Richard Dickson has highlighted steps to reduce Gap’s dependency on merchandise from China. By the end of 2025, the company aims for less than 3% of its merchandise to be sourced from China, ensuring no single country accounts for more than 25% of their sourcing by 2026. Meanwhile, Gap's recent quarterly performance was strong, with revenue hitting $3.46 billion and earnings per share at 51 cents, boosted by robust demand from Old Navy and the Gap brand.

Zymeworks' Cancer Drug Application Accepted by China’s NMPA

Zymeworks' Cancer Drug Application Accepted by China’s NMPA

36 minutes agoZYME

Zymeworks Inc. has achieved a major regulatory milestone with the National Medical Products Administration (NMPA) in China accepting its Biologics License Application (BLA) for zanidatamab. This development is crucial as it brings Zymeworks' targeted treatment for HER2-positive biliary tract cancer (BTC) a step closer to patients in China, expanding global access to potentially life-saving therapies. The NMPA's acceptance of the BLA is backed by conclusive data from the HERIZON-BTC-01 clinical trial. This trial indicated that zanidatamab achieved an objective response rate of 41.3%, with patients displaying a median duration of response lasting 12.9 months. These statistics highlight zanidatamab's effectiveness for patients with previously treated, unresectable, locally advanced, or metastatic HER2-positive BTC. Adding to the successful application acceptance, Zymeworks stands to gain financially through its partnership with BeiGene. According to Reuters, the company is set to receive an $8 million milestone payment following the NMPA's decision, with opportunities for additional milestones and royalties up to $164 million as the drug progresses in the Asia Pacific market. Meanwhile, Zymeworks continues to see international advancements, with the U.S. FDA having granted accelerated approval to zanidatamab in late 2024, marketed as Ziihera, further underscoring its global therapeutic potential.

Processa Pharmaceuticals Advances Cancer Drug Trials Despite No Recent ASCO Updates

Processa Pharmaceuticals Advances Cancer Drug Trials Despite No Recent ASCO Updates

51 minutes agoPCSA

As of May 30, 2025, there are no new data reports from Processa Pharmaceuticals presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting regarding their cancer drug development. However, the company has made notable strides in ongoing cancer drug trials, particularly with their NGC-Cap therapy. In October 2024, Processa kicked off a Phase 2 clinical trial for NGC-Cap, a drug combining PCS6422 and capecitabine, targeted at patients with advanced or metastatic breast cancer. This trial aims to assess the effectiveness of two different doses of NGC-Cap against the standard monotherapy capecitabine. Earlier in July 2024, the FDA granted clearance for Processa's Investigational New Drug application, paving the way for this trial's initiation. Significant positive data was also shared in April 2024 at the American Association for Cancer Research (AACR) Annual Meeting, showing enhanced 5-FU exposure and a favorable safety profile. Processa Pharmaceuticals has been proactive in its strategic approach. In January 2024, they successfully completed a Phase 1b safety evaluation, which helped establish recommended doses for the Phase 2 trial. Looking ahead, Dr. David Young, President of Research & Development at Processa, planned to present at the World Orphan Drug Congress USA 2025. This presentation will delve into applying FDA's Project Optimus principles to both oncology and rare disease treatment strategies, as reported by Nasdaq.